Furthermore, RCC’s strong reliance on CA9 and MCT networks may limit the monotherapy efficacy of GPR65-targeted strategies; signal ‘noise’ induced downstream of a GPR65 blockade between immune and metabolic signalling pathways could blunt therapeutic efficacy or induce unforeseen resistance mechanisms [99,109,110,147]. Here, GPR65 is linked to renal cell carcinoma.